Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Hyderabad, Jan. 09, 2026 (GLOBE NEWSWIRE) -- According to Mordor Intelligence, the non-invasive prenatal testing market is valued at USD 3.90 billion in 2025 and estimated to grow from USD 4.42...
-
-White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies- -Need for swift action by policymakers to...
-
Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM Expects to...
-
Attindas Hygiene Partners announces acquisition of Italy's Societá Italiana Lavorazione Cellulosa (SILC S.p.A.) through a share purchase agreement.
-
PLANEGG, Germany and MUNICH, Jan. 09, 2026 (GLOBE NEWSWIRE) -- A new study published in Pharmaceutics (https://doi.org/10.3390/pharmaceutics18010050) shows that LEON’s FR-JET® modular mixer...
-
LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
-
MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
-
SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing...
-
Financieringen går til fase 2-udvikling af ALV-100, IND-indsendelse af ALV-200 samt fremme af flere udviklingsprogrammer ALV-100, en bifunktionel GIPR-antagonist/GLP-1R-agonist, udviklet til varig...
-
Data from the first in human study on O3R-5671’s potent TNFα inhibition to be presented Dosing of the final cohort in the first in human study has been initiated Studies in ulcerative colitis and...